OrganiGram Holdings Inc. (OGI) Bundle
A Brief History of OrganiGram Holdings Inc. (OGI)
Founding and Early Years
Founding and Early Years
OrganiGram Holdings Inc., founded in 2013, is a Canadian licensed producer of cannabis products based in Moncton, New Brunswick. The company received its license from Health Canada to produce and sell medical cannabis on June 29, 2014. Initially, OrganiGram started its operations focusing on medical marijuana before the legalization of recreational cannabis in Canada.
Growth and Expansion
Following the legalization of recreational cannabis on October 17, 2018, OrganiGram experienced significant growth. The company reported a revenue of $23.2 million for the fiscal year ending August 31, 2019, an increase from $10.3 million in the previous year. The expansion led to the construction of a new facility, enhancing production capabilities.
Acquisitions and Strategic Partnerships
In 2020, OrganiGram acquired a majority stake in the cannabis biotechnology company, Edibles and Infusions Corporation, for approximately $22 million. This strategic move aimed to diversify OrganiGram’s product offerings and strengthen its position in the edibles market.
Recent Financial Performance
For the fiscal year ending August 31, 2022, OrganiGram reported revenue of $80.1 million, representing a year-over-year increase of 15%. The company achieved EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $10 million.
Market Position and Competition
As of October 2023, OrganiGram holds a market share of approximately 6.9% in the Canadian recreational cannabis sector, making it one of the top producers in the country. The company competes with other leading firms, including Canopy Growth and Aurora Cannabis.
Product Offerings and Innovations
OrganiGram offers a wide range of cannabis products, including dried flower, pre-rolls, oils, and edibles. As of 2023, the company launched over 20 new product lines, focusing on innovation in the craft cannabis segment.
Financial Overview
| Fiscal Year | Revenue (in millions) | EBITDA (in millions) | Net Income (in millions) |
|---|---|---|---|
| 2018 | $10.3 | - | - |
| 2019 | $23.2 | - | - |
| 2020 | $48.0 | - | - |
| 2021 | $69.9 | $5.0 | - |
| 2022 | $80.1 | $10.0 | $3.5 |
Stock Performance
OrganiGram's stock, traded on the NASDAQ under the ticker OGI, closed at $1.50 as of October 2023. The stock has seen fluctuations, with a 52-week range of $0.80 to $2.40.
Future Outlook
OrganiGram aims to expand further into international markets, with plans to enter several European countries by 2024. The company is investing in expanding its production facility to meet anticipated demand, budgeting an estimated $15 million for infrastructure improvements in the next fiscal year.
A Who Owns OrganiGram Holdings Inc. (OGI)
Ownership Structure
As of the latest financial filings, OrganiGram Holdings Inc. (OGI) has a diverse ownership structure, primarily composed of institutional investors, retail investors, and corporate insiders. The distribution of ownership is crucial for understanding the influence over the company's strategic direction and operational decisions.
| Owner Type | Percentage of Ownership |
|---|---|
| Institutional Investors | 22.56% |
| Retail Investors | 30.15% |
| Insider Ownership | 5.23% |
| Other Ownership | 42.06% |
Major Shareholders
Key shareholders play a significant role in the governance of OrganiGram. Below is a list of the major shareholders and their corresponding ownership stakes:
| Shareholder | Type | Shares Owned | Ownership Percentage |
|---|---|---|---|
| The Vanguard Group, Inc. | Institutional | 8,000,000 | 10.52% |
| Prospect Capital Corporation | Institutional | 5,500,000 | 7.25% |
| BlackRock, Inc. | Institutional | 7,200,000 | 9.63% |
| U.S. Global Investors, Inc. | Institutional | 2,200,000 | 2.91% |
| Insider Shareholdings | Insiders | 4,000,000 | 5.23% |
Recent Changes in Ownership
Recent filings indicate notable changes among the institutional owners, reflecting ongoing interest in the cannabis sector and OrganiGram specifically.
- In Q1 2023, The Vanguard Group increased its holdings by 1.5 million shares.
- Prospect Capital Corporation divested 0.5 million shares in mid-2023.
- BlackRock has maintained its position without significant changes in recent quarters.
Market Capitalization and Financial Data
OrganiGram Holdings Inc.'s market capitalization as of October 2023 stands at approximately $500 million. The company has shown fluctuations in its stock price, which is critical for potential investors.
| Financial Metric | Value |
|---|---|
| Market Capitalization | $500 million |
| Current Share Price | $1.25 |
| Price-to-Earnings Ratio (P/E) | 10.45 |
| Revenue (2022) | $78 million |
| Net Income (2022) | $5 million |
Investment Trends
The investment landscape for OrganiGram is influenced by broader market trends in the cannabis sector.
- Increased interest from institutional investors in the cannabis industry.
- A growing retail investor base as public sentiment shifts towards legalization.
- Potential for mergers and acquisitions as the market matures.
OrganiGram Holdings Inc. (OGI) Mission Statement
Company Overview
OrganiGram Holdings Inc. is a Canadian licensed producer of medical and recreational cannabis, established in 2013. The company operates a fully licensed facility in Moncton, New Brunswick.
Mission Statement
OrganiGram aims to produce high-quality, pharmaceutical-grade cannabis while maintaining a commitment to sustainability and community welfare. The mission emphasizes innovation and excellence in every aspect of production and distribution.
Core Values
- Quality: Ensuring products meet stringent industry standards.
- Integrity: Conducting business transparently and ethically.
- Innovation: Pioneering new processes and product lines.
- Sustainability: Implementing eco-friendly practices throughout operations.
- Community: Supporting local initiatives and responsible consumption.
Financial Performance
For the fiscal year 2023, OrganiGram reported revenue of $53.4 million, a year-over-year increase from the previous year's $50.8 million. The company's gross margin stood at 47%, reflecting operational efficiency amidst a competitive market.
| Financial Metric | Fiscal Year 2023 | Fiscal Year 2022 |
|---|---|---|
| Revenue | $53.4 million | $50.8 million |
| Gross Margin | 47% | 45% |
| Net Loss | ($5.2 million) | ($8.0 million) |
| Cash Flow from Operations | $1.2 million | ($2.4 million) |
| Total Assets | $243.7 million | $238.4 million |
Market Position
OrganiGram holds a significant position in the Canadian cannabis market with a market share of approximately 6.1% as of October 2023. The company continues to enhance its product offerings with a focus on both dried flower and value-added products.
Product Portfolio
- Dried Flowers
- Edibles
- Oils and Extracts
- Pre-Rolls
- Accessories
Sustainability Initiatives
OrganiGram is committed to sustainable business practices, having implemented energy-efficient technologies in its production facilities. The company has reduced its greenhouse gas emissions by 25% over the past two years. OrganiGram also emphasizes water conservation and waste reduction strategies.
Community Engagement
OrganiGram actively participates in community outreach programs, contributing over $1 million to local charities and initiatives in 2023. The company promotes responsible cannabis use and education programs among its consumers.
Future Outlook
Looking ahead, OrganiGram plans to expand its production capabilities and introduce new product lines aimed at the evolving consumer market. The anticipated introduction of new lines is expected to boost revenue by an estimated 15% in the next fiscal year.
How OrganiGram Holdings Inc. (OGI) Works
Company Overview
OrganiGram Holdings Inc. is a licensed producer of cannabis based in Moncton, New Brunswick, Canada. As of 2023, the company operates under the Cannabis Act of Canada and focuses on the cultivation, processing, and sale of cannabis products. The company is publicly traded on the TSX Venture Exchange under the ticker symbol OGI.
Production Facilities
OrganiGram's facilities encompass approximately 1.1 million square feet of production space. The company's state-of-the-art facility is designed to support large-scale cannabis cultivation, processing, and packaging. The facility includes:
- Indoor cultivation rooms for optimal environmental control
- Extraction areas for producing oils and concentrates
- Packaging and distribution centers
Financial Performance
As of the fourth quarter of 2023, OrganiGram reported the following financial data:
| Metric | Q4 2023 Amount (CAD) | Year-over-Year Growth (%) |
|---|---|---|
| Total Revenue | 42.1 million | 35% |
| Gross Margin | 12.5 million | 28% |
| Net Income | 3.2 million | 18% |
| Adjusted EBITDA | 8.4 million | 22% |
Product Lines
OrganiGram offers a diversified range of cannabis products, which includes:
- Dried flower
- Pre-rolls
- Oils and tinctures
- Edibles
- Topicals
As of 2023, the company has a significant market share within these segments, particularly in the dried flower and oil categories.
Sales and Distribution Channels
OrganiGram's products are sold through various channels:
- Provincial and territorial governments
- Licensed retailers across Canada
- Online sales platforms
The company reported in Q4 2023 that it had increased its distribution footprint to over 3,500 retail locations across Canada.
Research and Development
The company invests in R&D to enhance product offerings and cultivation techniques. In the fiscal year 2023, R&D expenses totaled approximately CAD 3 million, focusing on:
- Strain development
- New product formulations
- Enhanced cultivation technologies
Market Position and Strategy
OrganiGram positions itself as a premium cannabis producer. Key elements of its market strategy include:
- Focus on quality and consistency
- Brand development for customer loyalty
- Expansion into international markets
Recent Developments and Future Outlook
In 2023, OrganiGram expanded its production capacity to meet growing demand. The company plans to increase its market share in the rapidly evolving Canadian cannabis market, projecting an annual growth rate of approximately 30% through 2025. This is driven by:
- Product innovation
- Strategic partnerships
- Expansion into new markets
How OrganiGram Holdings Inc. (OGI) Makes Money
Revenue Streams
OrganiGram Holdings Inc. primarily generates revenue through the cultivation, production, and sale of cannabis products. The company operates in a highly regulated industry, primarily focusing on the legal cannabis market in Canada.
Product Lines
- Flower Products
- Extracts
- Pre-rolls
- Edibles
- Topicals
Financial Performance
For the fiscal year 2022, OrganiGram reported revenue of $53.3 million, representing an increase over the previous year.
Sales Volume and Market Share
In Q3 2023, OrganiGram sold approximately 12,000 kilograms of cannabis, showcasing a strong demand for its product offerings in the Canadian market.
Revenue Breakdown
| Product Type | Revenue (CAD) | Percentage of Total Revenue |
|---|---|---|
| Flower Products | $30 million | 56.3% |
| Extracts | $15 million | 28.1% |
| Pre-rolls | $5 million | 9.4% |
| Edibles and Topicals | $3.3 million | 6.2% |
Operational Efficiency
OrganiGram has invested in advanced cultivation technologies that have reduced production costs by approximately 25% since 2021.
Cost Structure
| Cost Type | Amount (CAD) | Percentage of Revenue |
|---|---|---|
| Cost of Goods Sold | $28 million | 52.5% |
| Operating Expenses | $18 million | 33.7% |
| Research and Development | $5 million | 9.4% |
| Administrative Expenses | $2 million | 3.8% |
Market Trends and Opportunities
The Canadian cannabis market is projected to grow at a CAGR of 18% through 2026, presenting OrganiGram with significant opportunities for revenue expansion.
Partnerships and Collaborations
OrganiGram has established partnerships with various retailers, increasing its distribution network to over 2,000 stores across Canada.
Future Projections
For the fiscal year 2023, OrganiGram is projecting a revenue increase of up to 30% compared to 2022, aiming to achieve approximately $69 million in sales.
Market Positioning
As of Q2 2023, OrganiGram holds a market share of approximately 5% in the Canadian cannabis sector, positioned as one of the leading producers in the industry.
Conclusion of Financial Overview
OrganiGram's strategic focus on high-quality cannabis products and operational efficiencies continues to drive its revenue growth and market share expansion in the competitive cannabis landscape.
OrganiGram Holdings Inc. (OGI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support